Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Revolve Wealth Partners LLC

Revolve Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 433 shares of the medical research company’s stock after buying an additional 55 shares during the period. Revolve Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $251,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Dark Forest Capital Management LP purchased a new stake in Thermo Fisher Scientific in the third quarter valued at $632,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at $2,679,000. Operose Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 250.0% in the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after buying an additional 75 shares during the period. O Shaughnessy Asset Management LLC raised its holdings in shares of Thermo Fisher Scientific by 1.8% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 14,012 shares of the medical research company’s stock valued at $7,092,000 after buying an additional 243 shares during the period. Finally, Mutual Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 6.4% in the 3rd quarter. Mutual Advisors LLC now owns 2,023 shares of the medical research company’s stock valued at $1,024,000 after buying an additional 122 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

TMO has been the topic of several research analyst reports. Citigroup initiated coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective on the stock. The Goldman Sachs Group boosted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Evercore ISI boosted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Jefferies Financial Group reissued a “buy” rating and set a $650.00 target price (up from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $607.94.

Thermo Fisher Scientific Stock Down 1.3 %

TMO opened at $550.78 on Friday. The business has a 50 day moving average price of $574.51 and a two-hundred day moving average price of $562.27. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The company has a market cap of $210.24 billion, a PE ratio of 35.33, a P/E/G ratio of 2.60 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The disclosure for this sale can be found here. Insiders sold 22,000 shares of company stock valued at $12,532,780 in the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.